Niagen Bioscience, Inc. (NAGE) Form 10-Q — Aug 4, 2026
Niagen Bioscience's second-quarter 2026 net sales slipped 4% year over year to $29.8 million, and net income fell to $1.0 million from $3.6 million a year ago as ingredients segment sales dropped 29% and sales-and-marketing spending rose $1.9 million. First-half net sales were roughly flat at $61.3 million with net income of $7.3 million, which included a $4.8 million gain on the February 2026 sale of the analytical reference standards and services segment for about $6.0 million in cash. Consumer products was the bright spot, with Tru Niagen sales up 6% to $24.2 million in the quarter on roughly $2.5 million of e-commerce growth, partially offset by a $2.3 million decline in sales to A.S.
Key figures
- Eps
- 0.01
- Revenue
- 29785000
- Net Income
- 963000
- Total Assets
- 106589000
- Cash Position
- 66740000
- Atm capacity
- 50000000
- H1 net sales
- 61259000
- H1 net income
- 7281000
- Diluted eps h1
- 0.09
- Buyback spend h1
- 5100000
- H1 net sales yoy
- -1%
- Q2 net sales yoy
- -4%
- Ingredients q2 yoy
- -29%
- Accumulated deficit
- 157247000
- H1 operating income
- 2276000
- Q2 operating income
- 700000
- Gain on segment sale
- 4800000
- Ingredients q2 sales
- 5387000
- Segment sale proceeds
- 6000000
- Shares repurchased h1
- 1173118
- H1 operating cash flow
- 1578000
- Consumer products q2 yoy
- +6%
- Q2 net income prior year
- 3609000
- Stock price june 30 2026
- 3.19
- Consumer products q2 sales
- 24162000
- Buyback remaining authorization
- 14600000
- Shares outstanding july 30 2026
- 79126002
- Prior year h1 operating cash flow
- 9133000
- Outstanding line of credit borrowings
- 0
- Asia retail partner receivables collected
- 1300000
- Qub deferred consideration carrying value
- 5700000
- Nrcl purchase obligation through june 2027
- 20500000
Price after filing
Close on the filing date to close N calendar days later (from $3.32). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.